Details for Patent: 10,328,037

Which drugs does patent 10,328,037 protect, and when does it expire?

Patent 10,328,037 protects PROCYSBI and is included in two NDAs.

Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 10,328,037

Title:	Methods for storing cysteamine formulations and related methods of treatment
Abstract:	Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
Inventor(s):	Desjardin; Michael (Aptos, CA), Johnson; Mark (Fort Collins, CO)
Assignee:	Horizon Orphan LLC (Lake Forest, IL)
Application Number:	16/195,481
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,328,037
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,328,037

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Horizon	PROCYSBI	cysteamine bitartrate	CAPSULE, DELAYED RELEASE;ORAL	203389-001	Apr 30, 2013		RX	Yes	No					Y
Horizon	PROCYSBI	cysteamine bitartrate	CAPSULE, DELAYED RELEASE;ORAL	203389-002	Apr 30, 2013		RX	Yes	Yes					Y
Horizon	PROCYSBI	cysteamine bitartrate	GRANULE, DELAYED RELEASE;ORAL	213491-001	Feb 14, 2020		RX	Yes	No					Y
Horizon	PROCYSBI	cysteamine bitartrate	GRANULE, DELAYED RELEASE;ORAL	213491-002	Feb 14, 2020		RX	Yes	Yes					Y